Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiangxi Univ. of Chinese Medicine butyrylcholinesterase compound 4d-13: sourced facts only. name: "Remarkably, compound 4d-13, which demonstrated the most potent inhibitory activity against butyrylcholinesterase, also afforded consistent neuroprotective effects compared with Galantamine against the injury induced by NMDA or L-(+)-Sodium glutamate in SH-SY5Y cells." [PMID:40318509]; target: "Remarkably, compound 4d-13, which demonstrated the most potent inhibitory activity against butyrylcholinesterase, also afforded consistent neuroprotective effects compared with Galantamine against the injury induced by NMDA or L-(+)-Sodium glutamate in SH-SY5Y cells." [PMID:40318509]; developer: "Shenyang Pharmaceutical University, School of Traditional Chinese Materia Medica, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China; National Pharmaceutical Engineering Center for Solid Preparation in Chinese Herbal Medicine, Jiangxi University of Chinese Medicine, Nanchang 330006, PR China." [PMID:40318509]; stage: "Morris water maze and step-down testing in vivo confirmed that 4d-13 could ameliorate scopolamine-induced cognitive deficits." [PMID:40318509]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jiangxi Univ. of Chinese Medicine butyrylcholinesterase compound 4d-13.